Enanta Historical Cash Flow

ENTA Stock  USD 8.60  0.23  2.60%   
Analysis of Enanta Pharmaceuticals cash flow over time is an excellent tool to project Enanta Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 93.8 M or Depreciation of 1.9 M as it is a great indicator of Enanta Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Enanta Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enanta Pharmaceuticals is a good buy for the upcoming year.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

About Enanta Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Enanta balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Enanta's non-liquid assets can be easily converted into cash.

Enanta Pharmaceuticals Cash Flow Chart

At present, Enanta Pharmaceuticals' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 93.8 M, whereas Change To Inventory is projected to grow to (13.9 M).

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Enanta Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Enanta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.At present, Enanta Pharmaceuticals' Change In Working Capital is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 93.8 M, whereas Change To Inventory is projected to grow to (13.9 M).

Enanta Pharmaceuticals cash flow statement Correlations

0.39-0.660.690.04-0.74-0.47-0.28-0.4-0.160.67-0.420.840.39-0.24-0.130.480.11-0.680.730.44
0.39-0.090.330.18-0.580.08-0.44-0.50.170.240.390.340.010.230.080.610.07-0.280.06-0.05
-0.66-0.09-0.610.210.760.770.240.460.18-0.690.78-0.37-0.720.390.15-0.10.090.83-0.87-0.06
0.690.33-0.61-0.18-0.58-0.22-0.7-0.56-0.180.96-0.30.580.21-0.28-0.090.56-0.36-0.640.52-0.15
0.040.180.21-0.18-0.040.10.20.280.88-0.420.130.01-0.190.10.860.380.230.15-0.14-0.08
-0.74-0.580.76-0.58-0.040.630.420.65-0.04-0.570.52-0.42-0.610.180.0-0.32-0.110.83-0.77-0.07
-0.470.080.77-0.220.10.63-0.220.070.2-0.340.8-0.05-0.650.550.210.17-0.340.62-0.9-0.14
-0.28-0.440.24-0.70.20.42-0.220.84-0.02-0.64-0.01-0.38-0.14-0.14-0.08-0.360.660.45-0.040.21
-0.4-0.50.46-0.560.280.650.070.840.09-0.570.2-0.43-0.43-0.30.1-0.20.480.64-0.29-0.02
-0.160.170.18-0.180.88-0.040.2-0.020.09-0.410.14-0.13-0.080.140.980.32-0.080.11-0.25-0.33
0.670.24-0.690.96-0.42-0.57-0.34-0.64-0.57-0.41-0.40.530.3-0.34-0.320.39-0.34-0.70.6-0.07
-0.420.390.78-0.30.130.520.8-0.010.20.14-0.4-0.12-0.690.450.080.27-0.060.63-0.81-0.13
0.840.34-0.370.580.01-0.42-0.05-0.38-0.43-0.130.53-0.120.150.06-0.10.43-0.24-0.470.370.6
0.390.01-0.720.21-0.19-0.61-0.65-0.14-0.43-0.080.3-0.690.15-0.38-0.07-0.130.02-0.570.590.09
-0.240.230.39-0.280.10.180.55-0.14-0.30.14-0.340.450.06-0.380.060.06-0.180.19-0.430.16
-0.130.080.15-0.090.860.00.21-0.080.10.98-0.320.08-0.1-0.070.060.36-0.150.08-0.24-0.36
0.480.61-0.10.560.38-0.320.17-0.36-0.20.320.390.270.43-0.130.060.36-0.01-0.250.02-0.2
0.110.070.09-0.360.23-0.11-0.340.660.48-0.08-0.34-0.06-0.240.02-0.18-0.15-0.010.160.160.17
-0.68-0.280.83-0.640.150.830.620.450.640.11-0.70.63-0.47-0.570.190.08-0.250.16-0.76-0.2
0.730.06-0.870.52-0.14-0.77-0.9-0.04-0.29-0.250.6-0.810.370.59-0.43-0.240.020.16-0.760.2
0.44-0.05-0.06-0.15-0.08-0.07-0.140.21-0.02-0.33-0.07-0.130.60.090.16-0.36-0.20.17-0.20.2
Click cells to compare fundamentals

Enanta Pharmaceuticals Account Relationship Matchups

Enanta Pharmaceuticals cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash35.9M(29.9M)(9.9M)41.4M(48.2M)(45.7M)
Stock Based Compensation19.6M21.0M27.0M28.2M26.8M14.0M
Free Cash Flow5.6M(70.7M)(86.9M)(112.2M)(96.7M)(91.9M)
Change In Working Capital12.9M(13.7M)6.8M8.0M9.2M9.7M
Begin Period Cash Flow51.8M87.7M57.8M48.0M89.4M93.8M
Other Cashflows From Financing Activities9.0M3.1M20.0M198.1M(27.6M)(26.2M)
Depreciation3.6M3.3M3.0M2.4M1.2M1.9M
Other Non Cash Items(3.5M)(2.0M)242K2.6M9.3M9.8M
Capital Expenditures1.4M750K2.1M9.1M17.9M18.8M
Total Cash From Operating Activities7.1M(70.0M)(84.8M)(103.2M)(78.8M)(74.8M)
Change To Account Receivables27.8M(84K)3.3M9.4M2.0M2.1M
Net Income(36.2M)(79.0M)(121.8M)(133.8M)(116.0M)(110.2M)
Total Cash From Financing Activities9.0M3.1M20.0M198.1M(27.6M)(26.2M)
End Period Cash Flow87.7M57.8M48.0M89.4M41.2M44.1M
Change To Liabilities1.8M(3.2M)3.8M(4.6M)(4.2M)(4.0M)
Sale Purchase Of Stock(1.5M)(534K)(1.2M)(3.8M)(3.4M)(3.2M)
Investments21.3M37.7M57.0M(53.6M)(61.6M)(58.5M)
Total Cashflows From Investing Activities(86.7M)19.8M37.0M54.9M63.1M66.3M
Change To Netincome10.3M26.4M19.4M27.2M31.3M32.9M
Change To Operating Activities(4.8M)(14.0M)6.8M(372K)(334.8K)(351.5K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(5.48)
Revenue Per Share
3.407
Quarterly Revenue Growth
(0.05)
Return On Assets
(0.17)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.